The University of Southern Denmark has approved researchers to proceed with a revised hepatitis B birth-dose study in Guinea-Bissau, according to a statement from Dean Jakob Grauslund on October 7 reported by Rolling Stone and carried October 8-9. The university said approval followed an independent assessment by its research ethics committee, and that Guinea-Bissaus final national authorisation is still required before the study can begin.
The trial, funded through the CDC and first announced in late 2025, examines the hepatitis B vaccine dose given at birth — an intervention used safely for decades — and was previously cancelled after expert criticism that withholding a proven intervention raises Helsinki Declaration concerns. Advocacy group Stand Up for Science condemned the revival on October 8 in uncompromising terms, promising renewed opposition.
Process is the careful readers focus. The university explained that prior approval by a Guinean panel precluded separate Danish regional or national review under Danish law, and that World Health Organization and European ethics networks were approached for independent assessment but said they could not conduct one. Those facts, drawn from the deans statement, neither convict nor vindicate the design; they map the governance maze through which it travelled.
Inside the CDC, sources told Rolling Stone, supporters awaited the Danish outcome before seeking revival — a detail reported as sourcing, not established as agency policy. Agency and investigator representatives did not respond to requests in the accounts reviewed, and their silence should be recorded rather than interpreted.
No enrolment can begin without Guinean authorisation on the universitys own account. The verified position is procedural: Danish ethical approval granted, final national permission pending, scientific and advocacy dispute fully joined. What happens in Bissau decides the rest.
For Guinea-Bissau, the pending national decision is therefore the ethical centre of gravity, whatever Copenhagen committees conclude. Local authorisation, community engagement and guaranteed care standards for enrolled infants will determine whether the study, if it proceeds, deserves the trust its sponsors request. International coverage should centre Guinean voices in that judgement rather than treating the country as a venue. Media Remarks will follow Bissaus decision and the reasoning published with it as the storys next verified chapter.
